Rabab Nasrallah, PhD is a Healthcare Investment Professional at Earlybird Venture Capital, investing in early-stage companies across digital health, medical devices, diagnostics, R&D platform technologies, and biopharma. Currently, Rabab is a board member of Grey Wolf Therapeutics and a board observer of ImCheck Therapeutics, Atlantic Therapeutics, Argá Medtech, and Priothera. Before joining Earlybird, Rabab was the program manager at INCUBATE, a startup accelerator at the University of Sydney, Australia. With an extensive research background, Rabab has held roles in leading global research organizations in Australia and the UK, including The George Institute for Global Health, Lowy Cancer Research Centre, Cancer Research UK, and Cambridge University. Rabab has received her PhD in regenerative medicine from UNSW Sydney and Cancer Research UK Manchester Institute. She has also completed a postdoctoral fellowship at the Babraham Institute in Cambridge, focusing on therapeutics in the immuno-oncology and auto-immune disease space.